Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-101 in Adult Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Sep 2022
Price :
$35
*
At a glance
- Drugs Acazicolcept (Primary) ; Acazicolcept (Primary)
- Indications Autoimmune disorders; Graft-versus-host disease; Haemophagocytic lymphohistiocytosis; Inflammation; Psoriatic arthritis
- Focus Adverse reactions; First in man
- Sponsors Alpine Immune Sciences
- 30 Aug 2022 According to an Alpine Immune Sciences media release, clinical update from this study will be presented at a an R&D Day on Monday, September 12, 2022.
- 08 Jun 2020 According to an Alpine Immune Sciences media release, data from this trial were presented during the SLE, Sjogren's, and APS-Treatment poster session of the European League Against Rheumatism (EULAR) E-Congress on Saturday, June 6, 2020.
- 08 Jun 2020 Results presented in an Alpine Immune Sciences media release.